Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185472 | 0.90 | HPGD (0.51) | DGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL661514 | 0.85 | DGAT1 (0.59) | DGAT1USP5ALDH1A1SMN1; SMN2 | |
| SCHEMBL10186290 | 0.84 | FFAR4 (0.46) | DRD4 | |
| SCHEMBL663307 | 0.83 | SMN1; SMN2 (0.43) | DRD4USP5ALDH1A1SMN1; SMN2 | |
| SCHEMBL663308 | 0.83 | SMN1; SMN2 (0.43) | DRD4USP5ALDH1A1SMN1; SMN2 | |
| SCHEMBL10184835 | 0.81 | HPGD (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10184275 | 0.80 | HPGD (0.54) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10186205 | 0.80 | DGAT1 (0.52) | DGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13117523 | 0.78 | DGAT1 (0.52) | DGAT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10185470 | 0.78 | NPC1 (0.55) | DGAT1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | DGAT1 1/4885DRD4 1215/4885USP5 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.